EMA announces orphan drug designation for BP1001 for AML treatment

Bio-Path Holding Inc. declares that European Medicine Agency has granted orphan drug Designation.

Release Date: 19-Nov-2016



Bio-Path Holding Inc. declares that European Medicine Agency has granted orphan drug Designation to BP1001 for treatment of acute myeloid leukemia (AML). BP1001 is introduced by Bio-Path Holding Inc. to fill the void of the treatments and medications for effective treatment of acute myeloid leukemia.

 

In order to get EMA designation of orphan drug, the therapy or treatment must be curing any of the rare life threatening disease with a prevalence of less than 5 in 10,000 people in the European Union. Orphan drug designation provides incentives designed to facilitate development including fee reductions for protocol assistance, scientific advice and importantly, may provide up to ten years of market exclusivity in the EU following product approval.

 

For Orphan Drug Clinical Insight Reports Contact:   neeraj@kuickresearch.com

Need custom market research solution? We can help you with that too.